ANDOVER, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that it will ring the Nasdaq Stock Market Opening Bell on December 22, 2025. The event will take place at the Nasdaq MarketSite in New York’s Times Square and will feature CEO Byrna Ganz and members of the Company’s leadership team ...

Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Latin Metals Inc. ("Latin Metals" or the "Company") - (TSXV: LMS, OTCQB: LMSQF), is pleased to announce that, further to the Company's news release dated December 9, 2025, it has obtained an interim order (the "Interim Order") of the Supreme Court of British ...

Core Insights - Aprea Therapeutics has made significant progress in its clinical programs and is optimistic about its growth potential in 2026 [2][10] Group 1: Clinical Programs - The lead program, APR-1051, a next-generation WEE1 inhibitor, is showing promising anti-tumor activity in the ongoing ACESOT-1051 dose-escalation study, with a notable 15% reduction in tumor burden observed [3][4] - The treatment has been well tolerated with no dose-limiting toxicities reported, and disease stabilization has been noted in several patients, with the longest duration of treatment reaching 222 days [3][4] - The company is expanding its clinical focus on HPV-positive patients due to early positive responses, aligning with preclinical data from MD Anderson Cancer Center [5] - Upcoming catalysts for APR-1051 include further safety and efficacy data expected in Q1 2026 and completion of dose escalation in 2026 [6] Group 2: ATR Inhibitor Program - The ATRN-119 program has reached its recommended Phase 2 dose for once-daily dosing, with a strategic shift towards evaluating combination therapies [7] - Enrollment in monotherapy dosing arms of the ABOYA-119 study is paused to conserve cash amid challenging fundraising conditions [7] - Future strategies may include combination therapies with DNA-damaging agents, supported by preclinical data indicating enhanced anti-tumor immune responses [8][9] Group 3: Financial Position - Aprea has completed a $3.1 million gross private placement financing, extending its cash runway into Q1 2027 [10][11] - The company emphasizes financial discipline and aims to enhance investor relations to better communicate its value proposition [11][12] Group 4: Company Overview - Aprea is focused on developing innovative cancer treatments that target cancer cell vulnerabilities while minimizing damage to healthy cells [14] - The company's lead programs, APR-1051 and ATRN-119, are both in clinical development for solid tumor indications [15]

WEST HOLLYWOOD, Calif. and TEL AVIV, Israel, Dec. 18, 2025 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a multi-domain technology company building next-generation autonomous robotics, RF imaging, and AI-driven sensing, today announced the completion of its acquisition of Solar Drone Ltd., adding a field-proven, AI-powered autonomous aerial platform designed for persistent operations across defense, security, and energy infrastructure. The transaction closed o ...

NEWPORT BEACH, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) ("Amaze" or the "Company"), a global leader in creator-powered commerce, today announced the appointment of Joel Krutz as its Chief Financial Officer (“CFO”). Krutz brings more than 20 years of senior financial leadership across public companies in media, technology, and digital infrastructure. His background includes extensive experience guiding complex global organizations, executing capital strategy, and s ...

DOWNEY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company, today announced the successful closing of its acquisition of a high-volume Bay Area cannabis retail dispensary through the purchase of all outstanding equity of the operating entity. The acquired dispensary is a well-established, fully licensed retail operator located in a major Northern California market and has gener ...

THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA. Details of the poster presentation are as follows: Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of ...

MELVILLE, N.Y., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Data Storage Corporation (Nasdaq: DTST) (“Data Storage” or the “Company”), today provided a letter to shareholders from its CEO, Chuck Piluso. Dear Valued Shareholders, As we look ahead to 2026, I would like to outline the strategic direction we plan to pursue while noting that as we progress through the Tender Offer process, expected to be completed on or about January 12th, we will gain a clear understanding of our available cash and can begin executing th ...

HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc.™ (Nasdaq: SKWD) ("Skyward Specialty" or "the Company"), a leader in the specialty property and casualty (P&C) market, and Sixfold (“Sixfold”), an AI underwriting company transforming insurance workflows, announce a strategic partnership to accelerate the Company’s progress toward fully AI-powered underwriting across its U.S.-based property and casualty lines. This collaboration reinforces Skyward Specialty’s long-standing com ...

Numerous BondBloxx ETFs hit key milestones, including first-of-its-kind private credit ETF PCMM, which recently marked its one-year anniversary amid industry accoladesLARKSPUR, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- BondBloxx Investment Management is today sharing an update on what has been a year of growth, innovation and recognition in 2025. BondBloxx is the first ETF provider founded with the aim of providing precision tools for fixed income investors, and 2025 provided a number of proof points showin ...